Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?

• Published in: Breast cancer research and treatment 2024-07, Vol.206 (1), p.45-56
• Main Authors: Tan, Chen-feng, Wang, Jun, Zhong, Xiao-rong, Dai, Ze-lei, Xiang, Zhong-zheng, Zeng, Yuan-yuan, Wei, Xiao-yuan, Xu, Ning-yue, Liu, Lei
• Format: Article
• Language: English
• Subjects: Breast cancer; Chemotherapy; Clinical Trial; Medicine; Medicine & Public Health; Metastases; Multivariate analysis; Oncology; Patients; Radiation therapy; Risk factors; Statistical analysis; Survival
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-024-07249-2

Purpose The significance of postmastectomy radiotherapy (PMRT) in breast cancer patients who initially have clinically node-positive (cN +) status but achieve downstaging to ypN0 following neoadjuvant chemotherapy (NAC) remains uncertain. This study aims to assess the impact of PMRT in this patient subset. Methods Patients were enrolled from West China Hospital, Sichuan University from 2008 to 2019. Overall survival (OS), Locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and breast cancer-specific survival (BCSS) were estimated using the Kaplan–Meier method and assessed with the log-rank test. The impact of PMRT was further analyzed by the Cox proportional hazards model. Propensity score matching (PSM) was performed to reduce the selection bias. Results Of the 333 eligible patients, 189 (56.8%) received PMRT, and 144 (43.2%) did not. At a median follow-up period of 71 months, the five-year LRFS, DMFS, BCSS, and OS rates were 99.1%, 93.4%, 96.4%, and 94.3% for the entire cohort, respectively. Additionally, the 5-year LRFS, DMFS, BCSS, and OS rates were 98.9%, 93.8%, 96.7%, and 94.5% with PMRT and 99.2%, 91.3%, 94.9%, and 92.0% without PMRT, respectively (all p-values not statistically significant). After multivariate analysis, PMRT was not a significant risk factor for any of the endpoints. When further stratified by stage, PMRT did not show any survival benefit for patients with stage II-III diseases. Conclusion In the context of comprehensive treatments, PMRT might be exempted in ypN0 breast cancer patients. Further large-scale, randomized controlled studies are required to investigate the significance of PMRT in this patient subset.